Recombinant MVA vaccine (Cedars Sinai Medical Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant MVA vaccine (Cedars Sinai Medical Center)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Live attenuated vaccine
Mechanisms of ActionImmunostimulantsTumor protein p53 inhibitors
TargetsTumor protein p53
Therapy Area/IndicationsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCedars-Sinai Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCedars-Sinai Medical Center
Active IndicationsN/A
Inactive IndicationsGastrointestinal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A